Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Unfurls Expansive Topic List To Guide Launch Of Tobacco Mission

This article was originally published in The Tan Sheet

Executive Summary

FDA's request for comments on regulating tobacco products omits few, if any issues, likely generating substantial input to implement the agency's new authorities

You may also be interested in...



FDA 'Program Alignment' Means Inspections Consistency To Supplement Industry

Reports are common about ORA officials not being knowledgeable about the agency's supplement manufacturing and marketing regulations or familiar with the commodity of dietary supplements, but relying on drug or food product manufacturing regulations when they inspect supplement facilities.

Turning Back Calendar Could Keep E-Cigarettes Available Without Approval

Exercising enforcement discretion concerning the grandfather date for e-cigarettes and other products covered in FDA’s proposed deeming rule would not be the agency’s first use of the enforcement tool in implementing Tobacco Control Act regulations.

Turning Back Calendar Could Keep E-Cigarettes Available Without Approval

Exercising enforcement discretion concerning the grandfather date for e-cigarettes and other products covered in FDA’s proposed deeming rule would not be the agency’s first use of the enforcement tool in implementing Tobacco Control Act regulations.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103152

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel